Shares Homepage - BSE Sensex, NSE Nifty, Latest Prices, Live News, Company Search, Result Annoucements, Company News, Top stories, Gainers Losers, Top Performers, Market Commentary, Live Quotes, Bulk Deals
India's preferred Personal finance destination
Home Shares News Centre F&O Mutual Funds IPO Portfolio Commodity Loans Financial Planning Insurance About Us
Markets Companies Research Industries E-Mail Page
Wealth Tracker    Newsletter   Tax Corner NRI Centre Forums E-Mail Chat Masala Feedback
my Last 5 Scrips
Company BSE Price(Rs) % Chg
Hindalco 141.30 4.40
Tata Mot 428.65 4.24
Bhel 181.05 3.10
Tata Stl 418.80 1.22
Ntpc Ltd 123.05 0.37
Clear All Clear Last
Shares
NSE Live
Nifty Live Prices
Live Quotes
Top Gainers/Losers
Top 10 Turnover
No Delivery Stocks
BSE Live
BSE30 Live Prices
Live Quotes
Top Gainers/Losers
Top 10 Turnover
No Delivery Stocks
Market Pulse
Leaders
Laggards
FII Activity
Mutual Fund Activity
Meetings
Results Watch
Results Calendar
Results Announced
IPO Watch
Company
Snapshots
Quotes
Charts
Financials
Recent News
Broker Research
Meetings
Research Tutorial
Discussion Forum
Research
Research Reports
Sector Watch
Economy Watch
Snapshot-Natco Pharma Limited
Natco Pharma Limited
Sector:Pharmaceuticals Pharmaceuticals - Formulations
BSE:524816NSE:NATCOPHARMBloomberg:NTCPH@INReuters:NATP.BO
Market Lot: 1Face Value: 10ISIN Demat: INE987B01018
QuotesSnapshotChartsFinancialsResearchRecent News
Peer GroupAGM/AMMF HoldingDiscussion ForumBSE/NSE NoticesBSE/NSE Deals

 
 
Recent Developments
04-APR-14 NATCO Pharma today announced that the United States Patent and Trademark Office (the PTO) issued a final office action rejecting Teva's application seeking a reissue of U.S. Patent No. 5,800,808 (808 Patent), which was found to be invalid by the court of appeals for the Federal Circuit in July 2013. 01-APR-14 NATCO Pharma announced that the US Supreme Court agreed to hear appeal in a patent fight on Copaxone. 18-MAR-14 Natco Pharma...   More..
Business Profile Future Plans
One To One
Recent news
Latest News
US PTO rejects patent reissue application on Copaxone(R)  -IRIS 04-Apr-14
Previous

More


Brief Financials (in Rs. Mn.) 
Period ending (months)31-Dec-2013(9)31-Mar-2013 (12)31-Mar-2012 (12)
Net sales 4276.505143.304304.20
Other Income63.20119.4032.70
Total Income4339.705262.704336.90
Cost of goods sold3191.604023.303500.20
OPBDIT1148.101239.40836.70
PAT838.50781.30621.30
Gross Block---
Equity capital330.70313.70311.50
EPS (Rs.)-24.9121.39
DPS (Rs.)---
BV (Rs.)---
P/E range (x)-13.25 - 20.289.22 - 16.90
Debt / Equity (x)---
Operating margin (% of OI)26.523.619.3
Net margin (% of OI)19.314.814.3
Detailed Financials
Income 
Statement
Balance Sheet Latest 
Quarterly/Halfyearly
Ratio Analysis Share Statistics
Price Charts
Scrip Information



Registered Office
ADDRESS
Natco House
Road No 2
Banjara Hills
Hyderabad
Andhra Pradesh-500 033
PHONE
(040) 2354 7532
FAX
(040) 2354 8243
 
Board of Directors
NSE/BSE Announcements


Home | Shares | F&O | Mutual Funds | Loans | Insurance | News Centre
Trade On-line | Wealth Tracker | Newsletters | Tax Corner | NRI Centre | Forums | E-mail | Chat | Search in myiris | Advertise
All rights reserved. IRIS Business Services Limited
Disclaimer